Evidence map›Paper›PMID 25661192›Full record

ArticleACS nano2015

pH-activated nanoparticles for controlled topical delivery of farnesol to disrupt oral biofilm virulence.

Benjamin Horev, Marlise I Klein, Geelsu Hwang, Yong Li, Dongyeop Kim, Hyun Koo, Danielle S W Benoit

Open access · greenAbstract read
In one paragraph

Article in ACS nano, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed, 1 pooled it
25.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 1 synthesis or guideline pooled it, 332 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Benjamin Horev†Department of Biomedical Engineering, ‡Center for Oral Biology, ⊥Department of Chemical Engineering, and #Center of Musculoskeletal Research, University of Rochester, Rochester, New York 14627, United States.
Marlise I Klein†Department of Biomedical Engineering, ‡Center for Oral Biology, ⊥Department of Chemical Engineering, and #Center of Musculoskeletal Research, University of Rochester, Rochester, New York 14627, United States.
Geelsu Hwang†Department of Biomedical Engineering, ‡Center for Oral Biology, ⊥Department of Chemical Engineering, and #Center of Musculoskeletal Research, University of Rochester, Rochester, New York 14627, United States.
Yong Li†Department of Biomedical Engineering, ‡Center for Oral Biology, ⊥Department of Chemical Engineering, and #Center of Musculoskeletal Research, University of Rochester, Rochester, New York 14627, United States.
Dongyeop Kim†Department of Biomedical Engineering, ‡Center for Oral Biology, ⊥Department of Chemical Engineering, and #Center of Musculoskeletal Research, University of Rochester, Rochester, New York 14627, United States.
Hyun Koo†Department of Biomedical Engineering, ‡Center for Oral Biology, ⊥Department of Chemical Engineering, and #Center of Musculoskeletal Research, University of Rochester, Rochester, New York 14627, United States.
Danielle S W Benoit†Department of Biomedical Engineering, ‡Center for Oral Biology, ⊥Department of Chemical Engineering, and #Center of Musculoskeletal Research, University of Rochester, Rochester, New York 14627, United States.
University of Rochester · USUniversity of Pennsylvania · US

Funding

Evaluation of a Novel Anti-Caries Approach to Modulate Virulence of S. mutansR01DE018023 · NIDCR · UNIVERSITY OF ROCHESTER · PI KOO, HYUN · 2008 to 2019
$3.4M
Women's Health and the Environment over the Entire Lifespan (WHEEL)K12ES019852 · NIEHS · UNIVERSITY OF ROCHESTER · PI CORY-SLECHTA, DEBORAH A · 2010 to 2014
$1.8M
Training Program in Oral ScienceR90DE022529 · NIDCR · UNIVERSITY OF ROCHESTER · PI OVITT, CATHERINE, YULE, DAVID I · 2011 to 2021
$877k
NIDCR NIH HHS R01 DE018023NIDCR NIH HHS R01DE018023NIDCR NIH HHS R90 DE022529NIDCR NIH HHS R90DE022529NIEHS NIH HHS K12 ES019852NIEHS NIH HHS K12ES019852
6 · The paper itself

Abstract

Development of effective therapies to control oral biofilms is challenging, as topically introduced agents must avoid rapid clearance from biofilm-tooth interfaces while targeting biofilm microenvironments. Additionally, exopolysaccharides-matrix and acidification of biofilm microenvironments are associated with cariogenic (caries-producing) biofilm virulence. Thus, nanoparticle carriers capable of binding to hydroxyapatite (HA), saliva-coated HA (sHA), and exopolysaccharides with enhanced drug release at acidic pH were developed. Nanoparticles are formed from diblock copolymers composed of 2-(dimethylamino)ethyl methacrylate (DMAEMA), butyl methacrylate (BMA), and 2-propylacrylic acid (PAA) (p(DMAEMA)-b-p(DMAEMA-co-BMA-co-PAA)) that self-assemble into ∼21 nm cationic nanoparticles. Nanoparticles exhibit outstanding adsorption affinities (∼244 L-mmol(-1)) to negatively charged HA, sHA, and exopolysaccharide-coated sHA due to strong electrostatic interactions via multivalent tertiary amines of p(DMAEMA). Owing to hydrophobic cores, nanoparticles load farnesol, a hydrophobic antibacterial drug, at ∼22 wt %. Farnesol release is pH-dependent with t1/2 = 7 and 15 h for release at pH 4.5 and 7.2, as nanoparticles undergo core destabilization at acidic pH, characteristic of cariogenic biofilm microenvironments. Importantly, topical applications of farnesol-loaded nanoparticles disrupted Streptococcus mutans biofilms 4-fold more effectively than free farnesol. Mechanical stability of biofilms treated with drug-loaded nanoparticles was compromised, resulting in >2-fold enhancement in biofilm removal under shear stress compared to free farnesol and controls. Farnesol-loaded nanoparticles effectively attenuated biofilm virulence in vivo using a clinically relevant topical treatment regimen (2×/day) in a rodent dental caries disease model. Strikingly, treatment with farnesol-loaded nanoparticles reduced both the number and severity of carious lesions, while free farnesol had no effect. Nanoparticle carriers have great potential to enhance the efficacy of antibiofilm agents through multitargeted binding and pH-responsive drug release due to microenvironmental triggers.

Indexed as

Administration, TopicalBiofilmsDelayed-Action PreparationsDental PellicleDrug CarriersDurapatiteFarnesolHumansHydrogen-Ion ConcentrationMouthPolysaccharides, BacterialStreptococcus mutansSurface PropertiesVirulenceDelayed-Action PreparationsDrug CarriersDurapatiteFarnesolPolysaccharides, Bacterialdental cariesdental pellicleexopolysaccharidesfarnesolmatrixnanoparticlespH-responsivepolymeric micellesStreptococcus mutans biofilms

Identifiers

PMID25661192
PMCPMC4395463
OpenAlexW2059631164

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.